By Chris Wack Syndax Pharmaceuticals shares were up 8% to $18 after the company said it saw positive data from trials of revumenib in combination with.
Incyte and Syndax Pharmaceuticals: Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
- Trial met its primary endpoint across all dose cohorts with 74% of patients at the 0.3 mg/kg dose achieving a complete or partial response within the first six months of treatment
- Data are.
Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Free Report) by 1.6% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 39,492 shares of the company’s stock after purchasing an additional 615 shares […]